Black Diamond Therapeutics (NASDAQ:BDTX) PT Raised to $15.00 at Piper Sandler

Black Diamond Therapeutics (NASDAQ:BDTX) had its price target raised by equities research analysts at Piper Sandler from $12.00 to $15.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target suggests a potential upside of 227.51% from the stock’s previous close.

Other analysts also recently issued research reports about the company. Raymond James initiated coverage on Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, September 18th. Finally, Wedbush reissued an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, September 10th.

Black Diamond Therapeutics Stock Performance

BDTX stock opened at $4.58 on Monday. Black Diamond Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $7.66. The business’s 50-day moving average is $5.63 and its two-hundred day moving average is $5.36. The company has a market cap of $257.64 million, a price-to-earnings ratio of -2.76 and a beta of 2.49.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities analysts predict that Black Diamond Therapeutics will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On Black Diamond Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC purchased a new position in shares of Black Diamond Therapeutics in the 1st quarter worth approximately $82,000. SG Americas Securities LLC purchased a new position in shares of Black Diamond Therapeutics in the 2nd quarter worth approximately $108,000. Jump Financial LLC boosted its holdings in shares of Black Diamond Therapeutics by 245.0% in the 4th quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock worth $109,000 after purchasing an additional 27,616 shares during the period. Algert Global LLC purchased a new position in shares of Black Diamond Therapeutics in the 2nd quarter worth approximately $133,000. Finally, Pale Fire Capital SE bought a new stake in shares of Black Diamond Therapeutics during the 4th quarter worth approximately $144,000. Hedge funds and other institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.